Drug delivery to the lungs of asthmatic patients using Dry Powder Inhalers: device and formulation matters!

This study will be presented at ERS 2019 at a thematic poster session on Tuesday October 1st between 12.50 pm and 2.40 pm.

In a FRI deposition study,  the lung deposition patterns of extrafine ICS/LABA to non-extrafine ICS/LABA combination from two different DPIs in asthmatic patients were compared.

Deposition percentages of extrafine and non-extrafine ICS/LABA fixed combinations

Results showed that intrathoracic deposition with extrafine formulation was much higher than for the non-extrafine formulation. This difference was even more pronounced when looking at the deposition in the peripheral airways, reflecting the difference in mass median aerodynamic diameter (MMAD) between formulations from both devices.

FRI deposition data suggest that the extrafine formulation is superior to larger particle formulations in consistently delivering both ICS and LABA to both the large and small airways.

Sorry, comments are closed for this post.